• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Sublocade vs SL Buprenorphine after Release from Jail
RESEARCH UPDATE

Sublocade vs SL Buprenorphine after Release from Jail

September 1, 2022
Peter J. Farago, MD.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Peter J. Farago, MD. Dr. Farago, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Lee JD et al, JAMA Netw Open 2021;4(9):e2123032

STUDY TYPE: Randomized comparative effectiveness trial

When people with opioid use disorder (OUD) are released from incarceration, they have a high risk of overdose—especially if they are not prescribed any medication for OUD. We know that methadone, sublingual buprenorphine/naloxone (SL-Bup), and injectable naltrexone all improve OUD outcomes in this population, but what about the relatively new long-acting injectable buprenorphine (XR-Bup, brand name Sublocade)? In this new study, researchers compared SL-Bup with XR-Bup to assess feasibility of administration and acceptability among people being released from incarceration.

Researchers enrolled 52 incarcerated, soon-to-be-released adults from New York City prisons who were already receiving SL-Bup for OUD. Half were randomized to start XR-Bup in prison with the goal of continuing it in the community. The other participants remained on SL-Bup. All participants were followed for eight weeks post-release. The primary clinical outcome was treatment retention.

The researchers first examined whether it was even feasible to give XR-Bup injections in incarceration settings. They concluded that it was. Most participants (21 of 26) received at least one dose of the medication before release (mean number of doses 2.3). Those on the injection required fewer daily jail clinic visits and had no incidents of diversion (whereas there were two incidents in the SL-Bup group). This led researchers to conclude that starting XR-Bup while incarcerated saves both time and labor.

Several post-release clinical outcomes were also superior in the XR-Bup group as compared to the SL-Bup group. There was a two-fold increase in buprenorphine treatment retention at week eight (69% vs 35%). The average length of time that patients stayed on buprenorphine after release was higher if they were receiving XR-Bup (6.1 weeks vs 2.6 weeks). There were more opioid-free urine tests in the XR-Bup group as compared to the SL-Bup group (55.4% vs 38.5%). No differences in the rates of serious adverse events were observed between the two groups, and no overdoses were observed in study participants.

The researchers did identify a few barriers to XR-Bup, including lack of knowledge about the formulation, perceived lack of access in the community, opposition to needle sticks, and a preference for staying with the familiar SL formulation. At the conclusion of the study, seven XR-Bup participants chose to switch back to SL-Bup, citing injection pain and preference.

Carlat Take

Although these findings are preliminary, and it will likely be some time before it is widely available in prison settings, XR-Bup appears to be a promising intervention for an extremely high-risk population. Expanding access to XR-Bup in the general outpatient setting will also be a critical step in making this intervention feasible.

KEYWORDS buprenorphine incarceration long-acting buprenorphine opioid use disorder
    Peter J. Farago, MD.

    Methamphetamines and Opioid-Related Overdose Risk

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Currently Available Cannabis Products
    Cannabis Use Disorder and Withdrawal
    Medicinal Cannabis
    Can Smoking Marijuana Reduce PTSD Symptoms?
    Sublocade vs SL Buprenorphine after Release from Jail
    Internet-Based Approaches for Gambling Issues
    Computer-Based Training for CBT for Women in Residential Treatments
    Learning Objectives, Cannabis, CATR, September/October 2022
    CME Post-Test - Cannabis, CATR, September/October 2022
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.